Neurogene Inc. (NGNE)
NASDAQ: NGNE · Real-Time Price · USD
21.28
+0.37 (1.77%)
Apr 8, 2026, 2:18 PM EDT - Market open
Neurogene Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
131
Market Cap
331.42M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 925.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Puma Biotechnology | 228.37M |
| LENZ Therapeutics | 19.09M |
| Opus Genetics | 14.20M |
| Prelude Therapeutics | 12.14M |
| Surrozen | 3.48M |
| Inhibikase Therapeutics | 1.00 |
| Adlai Nortye | -1.35M |
NGNE News
- 15 days ago - Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates - Business Wire
- 4 weeks ago - Neurogene to Participate in Stifel 2026 Virtual CNS Forum - Business Wire
- 5 weeks ago - Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 5 weeks ago - Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome - Business Wire
- 2 months ago - Neurogene to Participate in Upcoming Investor Conferences - Business Wire
- 2 months ago - Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 3 months ago - Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome - Business Wire
- 3 months ago - Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference - Business Wire